TABLE 2.
Clinical variables in patients with positive and negative galactomannan test
| Variable | % of patients with testa
|
P value | |
|---|---|---|---|
| Positive (n = 20) | Negative (n = 134) | ||
| Underlying liver disease | |||
| Hepatitis C virus (any) | 40 (8/20) | 43.3 (58/134) | NSb |
| Alcohol (any) | 15 (3/20) | 27.6 (37/134) | NS |
| Autoimmune | 20 (4/20) | 5.2 (7/134) | 0.030 |
| Immunosuppressive agent | |||
| Tacrolimus | 80 (16/20) | 74.6 (100/134) | NS |
| Cyclosporin A | 5 (1/20) | 5.2 (7/134) | NS |
| Mycophenolate mofetil | 0 (0/20) | 6.0 (8/134) | NS |
| Sirolimus | 15 (3/20) | 10.4 (14/134) | NS |
| Thymoglobulin | 35 (7/20) | 43.3 (58/134) | NS |
| CMV infection | 50 (10/20) | 42.5 (57/134) | NS |
| Intubation | 25 (5/20) | 10.4 (13/134) | NS |
| Rejection | 10 (2/20) | 20.1 (27/134) | NS |
| Dialysis | 40 (8/20) | 9.8 (14/133) | 0.002 |
| Antifungal agent use | 25 (5/20) | 15.7 (21/134) | NS |
a
The median length of ICU stay for patients with a positive test is 16 days, and that for patients with a negative test is 6 days (P = 0.002). The median length of the hospital stay is 26 days for patients with a positive test and 18 days for those with a negative test (not significant).
b
NS, not significant (P > 0.05).